Cell & Gene Therapy Drug Delivery Devices Market to grow at an Impressive CAGR During the Forecast Period
Rising awareness regarding the benefits of cell & gene therapy is driving Global Cell & Gene Therapy Drug Delivery Devices Market in forecast period.
According to TechSci Research report, “Global Cell & Gene Therapy Drug Delivery Devices Market By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags) By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis) By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others) By Method (In Vitro v/s Ex Vivo) By Region, Competition Forecast & Opportunities, 2026”, the global cell & gene therapy drug delivery devices market is projected to grow with an anticipated CAGR in the upcoming five years. The market growth can be attributed to rising number of patients suffering from chronic illness like cancer, diabetes, and other genetic disorders. Government aids, and private funds are strengthening the cell and gene therapy sector of healthcare industry. The field involves multiple researches that are ongoing and is directly influencing the growth of the global cell & gene therapy drug devices market. Multiple technically advanced devices are being launched and FDA is actively providing the approval for the usage of those devices thus, the factor is main cause of the market growth in the next five years.
Moreover, the market is experiencing a surge in demand of novel treatment development for rare diseases, along with rising biopharmaceutical expenses on research and development the market is anticipated to show its growth at the expected CAGR in the forecast period, 2022-2026. Also, clinical trials and latest cell & gene therapies are being conducted under the guidance of Food & Drug Administration, which is also an important factor that drives the market growth in the next five years.
Browse over XX market data Figures spread through 110 Pages and an in-depth TOC on “Global Cell & Gene Therapy Drug Delivery Devices Market”
https://www.techsciresearch.com/report/cell-and-gene-therapy-drug-delivery-devices-market/7364.html
Cell & gene therapy involves extraction of cells, protein, and genetic material like DNA from the donor which is then altered to provide the required result and thus a highly personalized therapy. The genetic material like DNA in humans, carry genetic information that translates into proteins that perform various functions in the body. In the cell & gene therapy, the genetic material in extracted from the cell and the DNA is altered using various methods of insertion, deletion, replacement, etc. Now the altered DNA, multiplies and proteins are made, that either is a treatment for the disease, or inhibits the proteins that are causing the disease. The developmental research has devised drug delivery system that are effective and long-lasting over traditional medicines.
The global cell & gene therapy drug delivery devices market is segmented by type, commercialized drugs, route of administration, method, regional distribution, and competitional landscape. Based on commercialized drugs the market is divided into Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, and Strimvelis. Luxturna is anticipated to dominate the market since it is a prescription gene therapy product that is used to treat inherited retinal diseases that is caused due to mutations in the genetic material. Number of patients suffering from retinal diseases are increasing at an alarming rate, thus the factor is anticipated to support the expected growth of the sub-segment of the market in upcoming five years. Kymriah, is a genetically modified, T-cell immunotherapy drug that is for the treatment of patients aged 25 years, with B-cells precursor acute lymphoblastic leukemia that is in a relapse stage. Provenge is a prescription medicine genetically modified to treat advanced prostate cancer in men. The genetically modified drugs are FDA approved and commercialized thereby driving the market growth of global cell & gene therapy drug delivery devices market in next five years by increasing the demand for these drug deliveries.
Some of the major competitors in the market are Becton, Dickinson, and Company, Novartis AG, Amgen Inc., Kite Pharma, Inc., Pfizer, Inc., Bausch & Lomb Incorporated, Bluebird bio, Inc., Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), Dendreon Pharmaceuticals LLC., Helixmith Co., Ltd (ViroMed Co., Ltd), Orchard Therapeutics plc, Renova Therapeutics, Spark Therapeutics, Inc., uniQure N.V., Vericel Corporation, among others. Top players have incorporated certain strategies like partnerships and investments in the research and development of the technically advanced products to excel their position in the competitive landscape of the market.
Download Sample Report @https://www.techsciresearch.com/sample-report.aspx?cid=7364
Customers can also request for 10% free customization on this report.
“With an excellent service in healthcare industry and its technologically sound sector North American region is anticipated to dominate the market. Maximum number of top players are present in the same region in large economy like United States, and Canada. Also, the healthcare industry in these large economies possesses high adoption rate of the advanced cell & gene therapy procedure that are expected to drive the market growth. Top international players may seek opportunities in the Asia Pacific market since the region is practically untapped and the developing countries like India, China, are gaining awareness about the novel systems,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based Global management consulting firm.
“Global Cell & Gene Therapy Drug Delivery Devices Market By Type (Subretinal Injection Cannula, Extension Tube, Intravenous Catheter, Sterile Insulin Syringe, Prefilled Syringe, Infusion Bags) By Commercialized Drugs (Luxturna, Kymriah, Yescarta, Zolgensma, Provenge, Strimvelis) By Route of Administration (Oral, Intravenous, Ocular, Transdermal, Others) By Method (In Vitro v/s Ex Vivo) By Region, Competition Forecast & Opportunities, 2026”, has evaluated the future growth potential of global cell & gene therapy drug delivery devices and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global cell & gene therapy drug delivery devices.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com/
